Photo - ENZYME2 Pharmaceuticals
46405

ENZYME2 Pharmaceuticals

Fighting Covid19 by using 3 ways for drug small molecules

Bulgaria
Market: Medicine
Stage of the project: Prototype or product is ready

Date of last change: 29.04.2020
Rating
equalizer from 2000
help
Calculated and estimated occupancy of the project (more about ratings)
My rating
1
2
3
4
5
6
7
8
9
10
Average rating:

Idea

Enzyme2 fighting Coronaviruses (Covid-19) by using 3 approaches for novel drug small molecules. Repurpose our first in class molecules in CCR5/CCR7 antagonists and SLC6A5 proprietary inhibitors and optimize our new ACE2 allosteric binders for the treatment of all patients affected by COVID-19 and other related coronaviruses.

Current Status

We built unique drug candidates for treatment of pandemic COVID-19 & Coronaviruses by using 3 approaches with novel first in class drug molecules.

Market

Current Market Potential Validation: https://coronavirus.jhu.edu/map.html

Apart from the tragic human consequences of the COVID-19 coronavirus epidemic, the economic uncertainty it has sparked will likely cost the global economy $ 1-2 Trillion in 2020
Source: according to the UN’s trade and development agency, UNCTAD

Problem or Opportunity

We built unique drug candidates for treatment of pandemic COVID-19 & Coronaviruses

Solution (product or service)

We built unique drug candidates for treatment of pandemic COVID-19 & Coronaviruses
Our novel small molecules contributes to: • Treatment of pandemic COVID-19 & Coronaviruses
• Reduces direct economic healthcare costs • Positive social and economic impact globally
By using:
- Micar21 new classes of Glycine transporter 2 (GlyT2) Inhibitors
- Micar21 the first class of “Ortho” CCR7 antagonists

Competitors

Micar21 in World analytic reports / COMPETITORS

Micar21, is one of the world’s 198 companies in Roots Analysis Study report: “In Silico/Computer-Aided Drug Discovery Services Market 2020-2030” Source: https://www.rootsanalysis.com/reports/view_document/in-silico-drug-discovery/298.html

Micar21, is one of the world’s 130 companies in Deep Knowledge Analytics report: AI for Drug Discovery Landscape 2018, 2019, 2020
Source: https://www.dka.global/

Micar21, is one of the world’s 250 companies in Roots Analysis Study report: “Computer-Aided Drug Discovery Services Market 2018-2030”
Source: https://www.rootsanalysis.com/reports/view_document/computer-aided-drug-discovery-services-market-2018-2030/207.html

16 Deep Tech Startups From The Balkans To Watch In 2020
TrendingTopics
Source: https://www.trendingtopics.at/bulgaria/16-deep-tech-startups-from-the-balkans-to-watch-in-2020/

LANDSCAPE SOFIA 2020
TNW X
Source: http://tiny.cc/tt5nmz

Advantages or differentiators

The three ways approach of curing COVID-19 offers a very elegant and cost effective way and garantes success, while minimizing risks.

Finance

We can share business plan for next 20 years.

Business model

ENZYME2 business model is based on discovering and developing COVID-19 first in class candidates until Phase 2a “Proof of concept" (PoC) and licensing them to youour commercial partner.

Money will be spent on

Preclinical phase and IND for next 8 months to reach Clinical Phase I

Offer for investor

30 % share

Team or Management

Risks

The three ways approach of curing COVID-19 offers a very elegant and cost effective way and garantes success, while minimizing risks.

Incubation/Acceleration programs accomplishment

NA

Won the competition and other awards

7 awards last 2 years

Investor of the year 2018

Innovative Enterprise of the Year

Best Biotech Startup

Invention/Patent

3 different patents

Details for our IP’s you can talk with IP lawyer companies

Photos

Photo 1 - Fighting Covid19 by using 3 ways for drug small molecules
5,00
1
2
3
4
5
1 voice
Sign in/Sign up
arrow_back
EN
more_horiz
close
visibility127
star0
Add to favorites
Delete from favorites
share
close
thumb_up0
Like
Unlike
Idea
Current Status
Market
Problem or Opportunity
Solution (product or service)
Competitors
Advantages or differentiators
Finance
Invested in previous rounds, $
Business model
Money will be spent on
Offer for investor
Team or Management
Mentors & Advisors
Lead investor
Risks
Incubation/Acceleration programs accomplishment
Won the competition and other awards
Invention/Patent
Photos
Product Video